Literature DB >> 21492260

Nasal immunization of mice with Lactobacillus casei expressing the pneumococcal surface protein C primes the immune system and decreases pneumococcal nasopharyngeal colonization in mice.

Marília de Lúcia Hernani1, Patrícia Cristina Duarte Ferreira, Daniela Mulari Ferreira, Eliane Namie Miyaji, Paulo Lee Ho, Maria Leonor Sarno Oliveira.   

Abstract

Streptococcus pneumoniae colonizes the upper respiratory tract of healthy individuals, from where it can be transmitted to the community. Occasionally, bacteria invade sterile niches, causing diseases. The pneumococcal surface protein C (PspC) is a virulence factor that is important during colonization and the systemic phases of the diseases. Here, we have evaluated the effect of nasal or sublingual immunization of mice with Lactobacillus casei expressing PspC, as well as prime-boosting protocols using recombinant PspC, on nasopharyngeal pneumococcal colonization. None of the protocols tested was able to elicit significant levels of anti-PspC antibodies before challenge. However, a significant decrease in pneumococcal recovery from the nasopharynx was observed in animals immunized through the nasal route with L. casei-PspC. Immune responses evaluated after colonization challenge in this group of mice were characterized by an increase in mucosal anti-PspC immunoglobulin A (IgA) 5 days later, a time point in which the pneumococcal loads were already low. A negative correlation between the concentrations of anti-PspC IgA and pneumococcal recovery from the nasopharynx was observed, with animals with the lowest colonization levels having higher IgA concentrations. These results show that nasal immunization with L. casei-PspC primes the immune system of mice, prompting faster immune responses that result in a decrease in pneumococcal colonization.
© 2011 Federation of European Microbiological Societies. Published by Blackwell Publishing Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21492260     DOI: 10.1111/j.1574-695X.2011.00809.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  18 in total

Review 1.  Bioengineered probiotics, a strategic approach to control enteric infections.

Authors:  Mary Anne Roshni Amalaradjou; Arun K Bhunia
Journal:  Bioengineered       Date:  2013-01-17       Impact factor: 3.269

2.  Characterization of macrophage-activating lactic acid bacteria isolated from Mukeunji.

Authors:  Jae-Hwan Kim; Jingmei Li; Seon-Kyeong Han; Pei Qin; Jushin Kim; Yeseul Park; Shin-Young Lee; Yeun Hong; Wooki Kim; Hae-Yeong Kim
Journal:  Food Sci Biotechnol       Date:  2016-04-30       Impact factor: 2.391

3.  Pneumococcal Adhesins PavB and PspC Are Important for the Interplay with Human Thrombospondin-1.

Authors:  Ulrike Binsker; Thomas P Kohler; Krystin Krauel; Sylvia Kohler; Hansjörg Schwertz; Sven Hammerschmidt
Journal:  J Biol Chem       Date:  2015-04-20       Impact factor: 5.157

4.  Immunogenic Properties of Lactobacillus plantarum Producing Surface-Displayed Mycobacterium tuberculosis Antigens.

Authors:  Katarzyna Kuczkowska; Charlotte R Kleiveland; Rajna Minic; Lars F Moen; Lise Øverland; Rannei Tjåland; Harald Carlsen; Tor Lea; Geir Mathiesen; Vincent G H Eijsink
Journal:  Appl Environ Microbiol       Date:  2016-12-30       Impact factor: 4.792

Review 5.  Engineering commensal bacteria for prophylaxis against infection.

Authors:  Yih-Lin Goh; HongFei He; John C March
Journal:  Curr Opin Biotechnol       Date:  2012-03-28       Impact factor: 9.740

6.  Immunization of mice with Lactobacillus casei expressing a beta-intimin fragment reduces intestinal colonization by Citrobacter rodentium.

Authors:  P C D Ferreira; J B da Silva; R M F Piazza; L Eckmann; P L Ho; M L S Oliveira
Journal:  Clin Vaccine Immunol       Date:  2011-09-07

Review 7.  Peptide-Based Vaccines for Tuberculosis.

Authors:  Wenping Gong; Chao Pan; Peng Cheng; Jie Wang; Guangyu Zhao; Xueqiong Wu
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 8.  Serotype-independent pneumococcal vaccines.

Authors:  Eliane Namie Miyaji; Maria Leonor Sarno Oliveira; Eneas Carvalho; Paulo Lee Ho
Journal:  Cell Mol Life Sci       Date:  2012-12-27       Impact factor: 9.261

Review 9.  Human Microbiome Engineering: The Future and Beyond.

Authors:  Arunava Kali
Journal:  J Clin Diagn Res       Date:  2015-09-01

Review 10.  Prophylactic vaccine delivery systems against epidemic infectious diseases.

Authors:  Chao Pan; Hua Yue; Li Zhu; Guang-Hui Ma; Heng-Liang Wang
Journal:  Adv Drug Deliv Rev       Date:  2021-07-17       Impact factor: 17.873

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.